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Defibrillation Thresholds
Testing of Implantable
Cardioverter-Defibrillators at Implantation
I read with interest the reports on defibrillation testing (DFT)
during implantable cardioverter-defibrillator (ICD) implantation
published recently in JACC (1,2). There is a significant, albeit low,
risk to serious complications including death during DFT testing.
If the implantation data as measured through the device are
satisfactory, then should we induce ventricular fibrillation (VF) in
a patient who has poor cardiac function? Should we crash a brand
new car during its “test-drive” to see whether the airbags will
deploy? The following cases, which are mere examples, demon-
strate the professional and moral dilemma of DFT testing.
Two patients with severe cardiomyopathy underwent ICD
implantation with excellent parameters. In the first case, during
DFT testing, first shock to provide a 10-J safety margin and a
subsequent maximum output shock failed to defibrillate. External
defibrillation restored sinus rhythm but with severe electrome-
chanical dysfunction requiring emergent placement of a ventricular
assist device and subsequently a heart transplantation. Was car-
diomyopathy in itself responsible for the ICD failure? Did the
shocks cause electromechanical dysfunction? Could the patient
have survived an out-of-hospital VF episode? Did DFT testing
identify deficiencies at implant? In the second case, DFT testing
was not performed because of the presence of atrial fibrillation,
suboptimal anticoagulation profile, and evidence of sludge in the
left atrial appendage by a transesophageal echocardiogram. Elec-
tive cardioversion and DFT testing after six weeks of anticoagu-
lation was planned. Unfortunately, in the interim period, the
patient met with an unnatural mode of death. Subsequently, the
patient’s wife reported that “it may not mean much . . . but the
defibrillator did go off . . . many times . . . it did work . . . when my
husband died. . . .”
During automobile accidents the airbags drastically reduce
morbidity and mortality, but there is also a spectrum of injuries
associated with them (3,4). Taking the analogy of the airbags and the
ICDs, both of which reduce fatalities, perhaps in the case of the first
patient, the “airbag” in itself was not adequate to prevent the fatality
and, if anything, perhaps caused “airbag”-associated injuries. In the
case of the second patient, the “airbag” deployed appropriately but
could not prevent a non-road-traffic-crash–related fatality.
Needless to say, until improvements in science and technology
provide conclusive evidence that the ICDs effectively and predictably
provide life-saving therapy without actually testing them at the time of
implantation, the dilemma of DFT testing will remain unsolved.
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REPLY
I thank Dr. Kantharia for his interest in our recent paper (1).
Identifying the optimal patient-specific implantable cardioverter-
defibrillator (ICD) system and its programming, without the need
for either ventricular fibrillation (VF) or shocks, is a major research
goal. The patients reported by Dr. Kantharia both emphasize the
importance of this goal and illustrate poignantly that it remains
beyond our grasp.
The first case highlights the unmet need of developing effective
treatment for life-threatening, post-VF electromechanical dys-
function (EMD) (2,3). Paradoxically, defibrillation testing may
have saved this patient’s life: If VF had occurred as an outpatient,
either defibrillation would have failed or the postshock rhythm
would have been lethal EMD. To the best of my knowledge, fatal
postshock EMD has not been reported after an inappropriate
shock. Thus, postshock EMD probably is caused by a combination
of VF and shocks, often prolonged VF and multiple shocks.
The second patient died from failed defibrillation with an
untested ICD system. This case illuminates the need for a
shockless method of assessing ventricular defibrillation efficacy, or
at least a method that minimizes the risk of thromboembolism
from atrial cardioversion. One consideration is continuous rapid
atrial stimulation during ventricular defibrillation or vulnerability
testing.
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